BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32434118)

  • 1. Propensity score adjusted analysis of patients with isolated locoregional recurrence versus de novo locally advanced NSCLC treated with definitive therapy.
    Friedes C; Mai N; Fu W; Hu C; Han P; Marrone KA; Voong KR; Hales RK
    Lung Cancer; 2020 Jul; 145():119-125. PubMed ID: 32434118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is pneumonectomy justifiable for patients with a locoregional recurrence or persistent disease after curative intent chemoradiotherapy for locally advanced non-small cell lung cancer?
    Joosten PJM; Dickhoff C; van der Noort V; Klomp HM; van Diessen JNA; Dahele M; Bahce I; Veenhof AAFA; Smit EF; Hartemink KJ
    Lung Cancer; 2020 Dec; 150():209-215. PubMed ID: 33220611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pattern of failure and clinical value of local therapy for oligo-recurrence in locally advanced non-small cell lung cancer after definitive chemoradiation: Impact of driver mutation status.
    Zhang J; Mao J; Xu D; Jiang S; Guo T; Zhou Y; Chu L; Yang X; Chu X; Ni J; Zhu Z
    Cancer Med; 2023 Mar; 12(6):6971-6979. PubMed ID: 36524618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy.
    Garg S; Gielda BT; Kiel K; Turian JV; Fidler MJ; Batus M; Bonomi P; Sher DJ
    Pract Radiat Oncol; 2014; 4(5):342-348. PubMed ID: 25194104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should salvage surgery be considered for local recurrence after definitive chemoradiation in locally advanced non-small cell lung cancer?
    Schreiner W; Dudek W; Lettmaier S; Fietkau R; Sirbu H
    J Cardiothorac Surg; 2016 Jan; 11():9. PubMed ID: 26781697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer.
    Sher DJ; Gielda BT; Liptay MJ; Warren WH; Batus M; Fidler MJ; Garg S; Bonomi P
    Clin Lung Cancer; 2013 Jul; 14(4):370-5. PubMed ID: 23260389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A validation study on the lung immune prognostic index for prognostic value in patients with locally advanced non-small cell lung cancer.
    Zhang T; Xue W; Wang D; Xu K; Wu L; Wu Y; Zhou Z; Chen D; Feng Q; Liang J; Xiao Z; Hui Z; Lv J; Wang X; Deng L; Wang W; Liu W; Wang J; Zhai Y; Wang J; Bi N; Wang L
    Radiother Oncol; 2021 Mar; 156():244-250. PubMed ID: 33418003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Survival after Salvage Surgery for Local Failure after Definitive Chemoradiation Therapy for Locally Advanced Non-small Cell Lung Cancer.
    Schreiner W; Dudek W; Lettmaier S; Fietkau R; Sirbu H
    Thorac Cardiovasc Surg; 2018 Mar; 66(2):135-141. PubMed ID: 28992654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive model of the first failure pattern in patients receiving definitive chemoradiotherapy for inoperable locally advanced non-small cell lung cancer (LA-NSCLC).
    Zhu X; Hou R; Li X; Jiang C; Xia W; Fu X
    Radiat Oncol; 2020 Feb; 15(1):43. PubMed ID: 32070383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Bergamino M; Rullan AJ; Saigí M; Peiró I; Montanya E; Palmero R; Ruffinelli JC; Navarro A; Arnaiz MD; Brao I; Aso S; Padrones S; Cardenal F; Nadal E
    BMC Cancer; 2019 Feb; 19(1):165. PubMed ID: 30791870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of Elderly Patients Who Receive Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung Cancer.
    Zaki M; Dominello M; Dyson G; Gadgeel S; Wozniak A; Miller S; Paximadis P
    Clin Lung Cancer; 2017 Jan; 18(1):e21-e26. PubMed ID: 27567356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of epidermal growth factor receptor mutations on the efficacy of definitive chemoradiotherapy in patients with locally advanced unresectable stage III non-small cell lung cancer: a systematic review and meta-analysis.
    Qin Q; Peng B; Li B
    Expert Rev Anticancer Ther; 2019 Jun; 19(6):533-539. PubMed ID: 31104529
    [No Abstract]   [Full Text] [Related]  

  • 13. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study.
    Chang JY; Verma V; Li M; Zhang W; Komaki R; Lu C; Allen PK; Liao Z; Welsh J; Lin SH; Gomez D; Jeter M; O'Reilly M; Zhu RX; Zhang X; Li H; Mohan R; Heymach JV; Vaporciyan AA; Hahn S; Cox JD
    JAMA Oncol; 2017 Aug; 3(8):e172032. PubMed ID: 28727865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer.
    Shirasawa M; Yoshida T; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Watanabe SI; Ohe Y; Motoi N
    Eur J Cancer; 2020 Nov; 140():28-36. PubMed ID: 33039811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage surgery for locoregional recurrence or persistent tumor after high dose chemoradiotherapy for locally advanced non-small cell lung cancer.
    Dickhoff C; Dahele M; Paul MA; van de Ven PM; de Langen AJ; Senan S; Smit EF; Hartemink KJ
    Lung Cancer; 2016 Apr; 94():108-13. PubMed ID: 26973215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensity-Modulated Radiation Therapy May Improve Local-Regional Tumor Control for Locally Advanced Non-Small Cell Lung Cancer Compared With Three-Dimensional Conformal Radiation Therapy.
    Wang J; Zhou Z; Liang J; Feng Q; Xiao Z; Hui Z; Wang X; Lv J; Chen D; Zhang H; Ji Z; Cao J; Liu L; Jiang W; Men Y; Xu C; Dai J; Yin W; Wang L
    Oncologist; 2016 Dec; 21(12):1530-1537. PubMed ID: 27628491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemoradiation and surgery improves survival outcomes compared with definitive chemoradiation in the treatment of stage IIIA N2 non-small-cell lung cancer.
    Darling GE; Li F; Patsios D; Massey C; Wallis AG; Coate L; Keshavjee S; Pierre A; De Perrot M; Yasufuku K; Cypel M; Waddell T
    Eur J Cardiothorac Surg; 2015 Nov; 48(5):684-90; discussion 690. PubMed ID: 25567960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
    Sher DJ; Koshy M; Liptay MJ; Fidler MJ
    Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non-Small Cell Lung Cancer.
    Speirs CK; DeWees TA; Rehman S; Molotievschi A; Velez MA; Mullen D; Fergus S; Trovo M; Bradley JD; Robinson CG
    J Thorac Oncol; 2017 Feb; 12(2):293-301. PubMed ID: 27743888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Radiotherapy and Chemoradiotherapy for Locoregional Recurrence of Non-small-cell Lung Cancer Developing After Surgery.
    Nakamichi S; Horinouchi H; Asao T; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Ito Y; Watanabe SI; Ohe Y
    Clin Lung Cancer; 2017 Nov; 18(6):e441-e448. PubMed ID: 28583380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.